Journals / Journal of Basic and Clinical Health Sciences / 2020 / Cilt: 4 - Sayı: 3

Serum Fetuin A and Secreted Phosphoprotein 24 as Diagnostic Markers in Inflammatory Bowel Disease

Pages
318–323
Publication Date
2020-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median fetuin A levels were significantly lower in the UC 249 mg/L and CD 254 mg/L groups compared to HC 352 mg/L UC vs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: A completely satisfactory biomarker has yet to be identified for the diagnosis and characterization of inflammatory bowel disease IBD .
📊
Key Findings & Data:This study evaluated the utility of fetuin A and secreted phosphoprotein 24 kDa Spp24 as novel biomarkers in IBD.
💡
Conclusion & Impact:Median fetuin A levels were significantly lower in the UC 249 mg/L and CD 254 mg/L groups compared to HC 352 mg/L UC vs.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Fetuin A · inflammatory bowel disease · secreted phosphoprotein 24

Abstract

Purpose: A completely satisfactory biomarker has yet to be identified for the diagnosis and characterization of inflammatory bowel disease IBD . This study evaluated the utility of fetuin A and secreted phosphoprotein 24 kDa Spp24 as novel biomarkers in IBD. Methods: Ninety IBD patients, 54 with ulcerative colitis UC and 36 with Crohn’s disease CD , and 41 healthy controls HC were included. Serum fetuin A, Spp24, TNF-α, and IFN-γ levels were analyzed by ELISA. Serum C-reactive protein CRP levels were determined turbidimetrically by an automated procedure. Results: There were no significant differences in serum Spp24 levels among the UC 17.15 pg/mL, mean , CD 18.88 pg/mL , and HC 14.77 pg/mL groups P>0.05 . Median fetuin A levels were significantly lower in the UC 249 mg/L and CD 254 mg/L groups compared to HC 352 mg/L UC vs. HC P

🔖

Cite This Article

KARAKOYUN, I., ISMAN, F. K., BASOK, B. I., ARSLAN, F. D., CALİK, B., KAHRAMAN, N. G., AKBULUT, G., ULASOGLU, C. (2020). Serum Fetuin A and Secreted Phosphoprotein 24 as Diagnostic Markers in Inflammatory Bowel Disease. Journal of Basic and Clinical Health Sciences, Cilt: 4 - Sayı: 3, 318–323. https://ajindex.com/articles/163506

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. de Souza HSP, Fiocchi C. Immunopathogenesis of IBD. current state of the art. Nat Rev Gastroenterol Hepatol 2016;13:13–27. [CrossRef] 2. Hagel AF, de Rossi T, Konturek PC, et al. Plasma histamine and tumour necrosis factor-alpha levels in crohn’s disease and ulcerative colitis at various stages of disease. J Physiol Pharmacol 2015;66:549–556. http:// www.jpp.krakow.pl/journal/archive/08_15/pdf/549_08_15_article.pdf 3. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012;159:313–325. [CrossRef] 4. Wasinger VC, Yau Y, Duo X, et al. Low mass blood peptides discriminative of inflammatory bowel disease (IBD) severity: A quantitative proteomic perspective. Mol Cell Proteomics 2016;15:256–265. [CrossRef] 5. Liu Y, Chen X, Xu Q, et al. SPP2 mutations cause autosomal dominant retinitis pigmentosa. Sci Rep 2015;5:14867. [CrossRef] 6. Gurbuz C, Polat H, Yildirim A, Canat L, Bayram G, Çaskurlu T. The role of alpha2-heremans schmid glycoprotein (Fetuin-A) in the etiology of urolithiasis. Curr Urol 2010;4:10–14. [CrossRef] 7. Ombrellino M, Wang H, Yang H, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 2001;15:181–185. [CrossRef] 8. Bonyadi M, Abdolmohammadi R, Jahanafrooz Z, Somy MH, Khoshbaten M. TNF-alpha gene polymorphisms in Iranian Azari Turkish patients with inflammatory bowel diseases. Saudi J Gastroenterol 2014;20:108–112. [CrossRef] 9. Műzes G, Molnár B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol 2012;18:5848–5861. [CrossRef] 10. Manolakis AC, Christodoulidis G, Kapsoritakis AN, et al. α2- Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease. World J Gastroenterol 2017;23:437–446. [CrossRef] 11. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a crohn’s disease activity index. National cooperative crohn’s disease study. Gastroenterology 1976;70:439–444. [CrossRef] 12. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with crohn’s disease. Gastroenterology 2002;122:512–530. [CrossRef] 13. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of crohn’s disease: report of the working party for the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8–15. [Cros